Next Article in Journal
Activation and Antagonism of the OAS–RNase L Pathway
Previous Article in Journal
An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus in Mice
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Application of SORTS, a Novel Gene-Edited Cell Selection Method for HIV Study and Therapy †

by
Dmitriy Mazurov
1,2,*,
Alexandra Maslennikova
1,
Dmitriy Komkov
1 and
Anastasia Zotova
1
1
Cell and Gene Technology Group, Institute of Gene Biology RAS, Moscow 119334, Russia
2
NRC Institute of Immunology FMBA of Russia, Moscow 115478, Russia
*
Author to whom correspondence should be addressed.
Presented at Viruses 2020—Novel Concepts in Virology, Barcelona, Spain, 5–7 February 2020.
Proceedings 2020, 50(1), 13; https://doi.org/10.3390/proceedings2020050013
Published: 4 June 2020
(This article belongs to the Proceedings of Viruses 2020—Novel Concepts in Virology)

Abstract

:
We have recently developed surface oligopeptide knock-in for rapid target selection (SORTS), a novel method to isolate mammalian cells with gene modifications using FACS-sorting. It relies on CRISPR/Cas9-mediated targeted knock-in of a very short promoterless expression construct (250 bp) comprising a Flag or HA epitope embedded into the smallest GPI-protein CD52, and a polyA signal from the beta-globin. CD52 efficiently delivers the epitope to the cell surface, where it serves as a marker for selection, while polyA terminates transcription and silences target gene expression. Primarily, SORTS was developed to knock out genes encoding intracellular or secreted proteins, which cannot be used as markers for selection of live cells. Using in-frame modification of SORTS, we demonstrated the possibility of HIV-1 provirus inactivation via sorting of GPI-tag positive cells. In order to make the “cured” cells resistant to a subsequent HIV-1 infection, the epitope tag in the CD52 molecule was substituted by one of the fusion inhibitor peptides from the CHR-domain of gp41. We selected a series of cell-surface-expressed, GPI-anchored, C34-based peptides that confer a strong cellular resistance to HIV-1 infection mediated by NL4-3, JRFL, or ZM153 Env. These findings together with a monoclonal antibody raised against the C34 peptide provide an opportunity to generate and select HIV-resistant lymphocytes for a therapeutic goal. SORTS was also adapted to engineer transgenic HIV-1 effector Т cells and to study cell-to-cell transmission. To facilitate transgenesis, we developed a knock-in strategy to express GPI-tag from the intronic region of the human PPP1R12C gene (AAVS1 locus) and delivered FRT sites of recombination into both alleles. In summary, SORTS is a novel instrument to isolate rare cells with precise genomic modifications with broad applications, including HIV biology. This work was supported by the Russian Science Foundation (grant 18-14-00333) and the Russian Foundation for Basic Research (grants 18-29-07052, 18-04-01016).

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Mazurov, D.; Maslennikova, A.; Komkov, D.; Zotova, A. Application of SORTS, a Novel Gene-Edited Cell Selection Method for HIV Study and Therapy. Proceedings 2020, 50, 13. https://doi.org/10.3390/proceedings2020050013

AMA Style

Mazurov D, Maslennikova A, Komkov D, Zotova A. Application of SORTS, a Novel Gene-Edited Cell Selection Method for HIV Study and Therapy. Proceedings. 2020; 50(1):13. https://doi.org/10.3390/proceedings2020050013

Chicago/Turabian Style

Mazurov, Dmitriy, Alexandra Maslennikova, Dmitriy Komkov, and Anastasia Zotova. 2020. "Application of SORTS, a Novel Gene-Edited Cell Selection Method for HIV Study and Therapy" Proceedings 50, no. 1: 13. https://doi.org/10.3390/proceedings2020050013

Article Metrics

Back to TopTop